Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Ultragenyx Pharmaceuticals (NASDAQ:RARE) Shares Drop After Phase 3 Setrusumab Results

Ultragenyx Pharmaceuticals (NASDAQ:RARE), a company focusing on treatments for rare genetic diseases, reported Phase 3 results for setrusumab (UX143), a monoclonal antibody for osteogenesis imperfecta (OI), that did not achieve primary endpoints.

Team Kalkine | 29 December 2025

ACM Research (NASDAQ:ACMR) Stock Jumps 162% as Triata Capital Increases USD78M Stake

ACM Research (NASDAQ:ACMR) develops and sells single-wafer wet cleaning equipment, electro-chemical plating systems, and related technologies used in semiconductor manufacturing. Its revenue is primarily derived from direct sales and third-party representatives under the Ultra C brand.

Team Kalkine | 29 December 2025

DigitalBridge Group (NYSE:DBRG) Shares Jump on SoftBank USD4B Acquisition Deal

DigitalBridge Group (NYSE:DBRG), a global digital-infrastructure investor-operator, closed Monday at 15.27 USD, up 9.7%. The increase followed reports that SoftBank (OTC: SFTB.Y) agreed to acquire the company at 16 USD per share in cash. Trading activity surged to 86M shares, roughly 14 times the …

Team Kalkine | 29 December 2025

First Majestic Silver (NYSE:AG) Shares Dip as Precious Metal Prices Decline

First Majestic Silver Corp. (NYSE:AG) saw its shares decline 4.1% on December 29, reversing part of an earlier 6.9% drop. The pullback comes after a year in which the stock rose more than 217%, largely in line with gains in silver and gold prices.

Team Kalkine | 29 December 2025

Brokerage Ratings Mixed on DigitalBridge Group (NYSE:DBRG) Amid Recent Analyst Updates

Citizens JMP reiterated its “market perform” rating on DigitalBridge Group Inc. (NYSE:DBRG), according to a research note cited by Benzinga. The brokerage maintained its existing stance while keeping its valuation framework unchanged. The update followed recent trading activity and broader analyst commentary surrounding the …

Aditi Sarkar | 29 December 2025

TriSalus Life Sciences (NASDAQ:TLSI) Holds Mixed Analyst Ratings; Target at USD 11

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) are presently covered by five research firms, resulting in a consensus recommendation ofHold. The current analyst mix includes oneSellrating, oneHoldrating, and threeBuyratings. Based on updates issued over the past year, the average twelve-month price target across covering …

Aditi Sarkar | 29 December 2025

Are Analysts Aligned on SAB Biotherapeutics (NASDAQ:SABS) Stock Ratings?

Shares ofSAB Biotherapeutics, Inc. (NASDAQ:SABS)are currently followed by six research firms, with analyst coverage resulting in an average rating described asModerate Buy. According to available analyst data, one firm has issued aSellrating, four analysts have assignedBuyratings, and one has issued aStrong Buyrating. The average …

Aditi Sarkar | 29 December 2025

Global Markets Enter Holiday-Shortened Week With Cautious Tone Amid Policy and Geopolitical Crosscurrents

Market Movers :On Friday, the top gainers were A SPAC III Acquisition Corp. (+78.91%), followed by Paranovus Entertainment Technology Ltd. (+37.34%). On the contrary, Ascent Solar Technologies, Inc (-21.37%), and SuperX AI Technology Limited. (-17.13%) declined the most the same day.

Team Kalkine | 29 December 2025

Citius Oncology (NASDAQ: CTOR) Reports Quarterly Loss as Shares Tick Higher

Citius Oncology, Inc. (NASDAQ:CTOR) released its quarterlyearningsresults on December 23, reporting a loss for the period. The company postedearnings per share(EPS) of negative USD 0.06, according to data referenced by Zacks Investment Research. The results reflected continued losses during the quarter, consistent with the …

Team Kalkine | 28 December 2025

Baronsmead Second Venture Trust (LON: BMD): 38% Net Margin in Recent Earnings Update

Baronsmead Second Venture Trust plc (LON:BMD) announced its quarterlyearningsresults on Tuesday, according to data from Digital Look Earnings. The venture capital trust reportedearnings per shareof GBX 0.55 for the reporting period. Financial results showed a netmarginof 38.32%, whilereturn on equitywas recorded at 1.95%.

Team Kalkine | 28 December 2025
Support

Hi! How can we help you today?

Loading…